The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors

Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Invest
Asıl Yazarlar: Balbino, Bianca, Herviou, Pauline, Godon, Ophélie, Stackowicz, Julien, Goff, Odile Richard-Le, Iannascoli, Bruno, Sterlin, Delphine, Brûlé, Sébastien, Millot, Gael A., Harris, Faith M., Voronina, Vera A., Nadeau, Kari C., Macdonald, Lynn E., Murphy, Andrew J., Bruhns, Pierre, Reber, Laurent L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2020
Konular:
Concise Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269578/
https://ncbi.nlm.nih.gov/pubmed/31770111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129697
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller